BC
REGN icon

Banced Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

Banced Corp’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,152
Closed -$536K – 119
2016
Q2 		$536K Sell
1,152
-490
-30% -$189K 1% 37
2016
Q1 		$591K Buy
1,642
+284
+21% +$117K 1.03% 37
2015
Q4 		$737K Buy
1,358
+206
+18% +$112K 1.32% 22
2015
Q3 		$536K Sell
1,152
-100
-8% -$53.7K 0.99% 37
2015
Q2 		$639K Sell
1,252
-139
-10% -$67.8K 0.87% 33
2015
Q1 		$628K Sell
1,391
-290
-17% -$123K 0.89% 31
2014
Q4 		$690K Sell
1,681
-115
-6% -$45.2K 0.75% 33
2014
Q3 		$647K Buy
1,796
+279
+18% +$93.5K 0.75% 36
2014
Q2 		$428K Sell
1,517
-1,010
-40% -$299K 0.52% 77
2014
Q1 		$759K Buy
2,527
+1,662
+192% +$512K 0.79% 29
2013
Q4 		$238K Sell
865
-127
-13% -$36.5K 0.24% 157
2013
Q3 		$310K Buy
+992
New +$261K 0.31% 136

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Banced Corp's REGN Position: Q3 2016 in Review

Banced Corp sold out of Regeneron Pharmaceuticals (REGN) in Q3 2016, closing a stake of 1,152 shares — an estimated $536K sold.

Banced Corp first reported a position in REGN in Q3 2013 and held it in 12 quarters. The position peaked at $759K in Q1 2014. 555 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

  • Banced Corp reported no remaining Regeneron Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Banced Corp sold 1,152 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $536K.
  • Banced Corp first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 12 quarters.
  • Banced Corp's Regeneron Pharmaceuticals position peaked at $759K in Q1 2014.
  • 555 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on Banced Corp's 13F filing for Q3 2016, filed 12 Oct 2016.